경동제약

011040KOSDAQ의약품 제조업

54.3 / 100

Reference Date: 2026-06-10

Financial Score19.0 / 40

News Sentiment20.3 / 25

Momentum5.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 10.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongdong Pharmaceutical, established in 1976, is a company specializing in the manufacturing and sales of pharmaceuticals. Its business segments include pharmaceuticals (accounting for ~95% of sales), leasing, and others. Key products include DuoLoban tablets and Alpotin soft capsules, targeting rising demand due to aging populations and Western dietary habits. The company is expanding exports and developing new products, including OTC drugs and health supplements.

Number of Employees

363people

Average Salary

56.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

15.73Industry Average 11.933.0Point

Higher than industry avg (caution)

PBR

0.67Industry Average 0.894.0Point

In line with industry avg

ROE

3.76Industry Average 4.012.5Point

Below industry avg

Debt Ratio

10.24Industry Average 12.434.0Point

In line with industry avg

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲151.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.8% (improving, 3yr)

Detailed News Sentiment

5 totalPositive 4Neutral 0Negative 1Average Sentiment Score 81

Positive
대웅제약, 차임과 '듀피젠트' 바이오시밀러 개발 협력
대웅제약과 차임 바이오로직스의 협력으로 '듀피젠트' 바이오시밀러 개발 계약 체결, 경동제약 관련 직접적인 영향은 제한적이나 협력사와의 파트너십 강화로 긍정적 전망.
Positive
27兆 아토피 치료제 ‘듀피젠트’…대웅제약, 바이오시밀러 경쟁 뛰어....
경동제약과 관련된 바이오시밀러 개발 소식으로 인해 긍정적인 시장 반응 예상.
Negative
듀피젠트 바이오시밀러 경쟁 격화…대웅제약도 뛰어든다
듀피젠트 바이오시밀러 경쟁 심화로 경동제약의 시장 지위 약화 우려.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,970Won52-week high 6,20052-week low 4,970

1-month return1.0Point

1m -10.61% (falling)

Volume trend3.0Point

Volume flat

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-06-09
Neutral분기보고서 (2026.03)2026-05-14